MERIDEN, Conn., Oct. 29, 2015 /PRNewswire/ -- Protein Sciences Corporation, the makers of Flublok®Influenza Vaccine, announced today that Dr. Manon Cox, President and CEO, was elected as a 2015 Fellow of the International Society for Vaccines (ISV). The ISV is an esteemed organization dedicated to the development, advancement and use of vaccines to prevent and control disease. ISV Fellows represent a distinguished pool of scientists, doctors and professionals that have contributed significantly to this field. Past ISV Fellows include Sabin Gold Medal and Fleming Award Winner Dr. Stanley Plotkin, internationally renowned microbiologist Dr. Peter Palese, and industry leaders like Drs. Emilio A. Emini and Rino Rappuoli.
"I am deeply honored to be elected into this prestigious circle," said Dr. Cox. "Flublok is being recognized as a major advance and this appointment demonstrates that the vaccine industry recognizes that innovation in vaccines is much needed."
Dr. Indresh Srivastava, Vice President of Process and Analytical Development at Protein Sciences, has also been nominated to serve on the Executive Board for the ISV. Dr. Srivastava is a leading biochemist and vaccinologist and has been involved in the development of vaccines against malaria, HIV, SARS, HepC, Men B, West Nile and influenza in both academic and industrial settings for the last 25 years.
About Protein Sciences
Protein Sciences specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health through the creation of innovative vaccines and biopharmaceuticals.
Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, was approved by FDA in January 2013. Flublok is the only flu vaccine made in a 100% egg-free system using modern cell culture technology, making it unnecessary to use an infectious influenza virus or antibiotics in manufacturing. Flublok is highly purified and does not contain any preservatives (e.g., thimerosal, a mercury derivative), egg proteins, gelatin or latex. In addition, Flublok contains three times more antigen than traditional flu vaccines (3x45mcg hemagglutinin protein versus 3x15mcg hemagglutinin protein)*. Flublok is a perfect copy of the virus coat and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see Skowronski et al. (2014) PLOS ONE 9(3), e92153).
Healthcare professionals wishing to order Flublok should contact one of the following distributors:
Flublok Safety Information
Flublok is approved for people 18 and older to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Headache, fatigue or muscle ache may occur. Tell the doctor if you have ever experienced Guillain-Barre syndrome (severe muscle weakness) or have had a severe allergic reaction to any component of Flublok vaccine. Vaccination with Flublok may not protect all individuals. Clinical effectiveness in adults 50 and older is based on the immune response elicited by Flublok and not on demonstration of decreased influenza disease. Please see the complete Package Insert available at www.flublok.com or call 203-686-0800 for more information.
*Flublok demonstrated a higher antibody response to the A strains during 2 clinical trials in adults >50 years old. The B strain antibody response was comparable to traditional trivalent vaccines.
SOURCE Protein Sciences Corporation